Citations

Clear

3030 citation(s) found for "Susan, M".

Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Meletti, Stefano, Hanin, Aurelie, Bedin, Roberta , Burani, Margherita , Taruffi, Lisa , Urbano, Teresa, d’Achille, Fabio, Malerba, Mara, Basha, Maysaa M., Eschbach, Krista, Farias-Moeller, Raquel, Gerard, Elisabeth E., Gofton, Teneille, Gopaul, Margaret T., Haider, Hiba A. , Hantus, Stephen , Herman, Susan, Kang, Peter, Kandula, Padmaja , Taraschenko, Olga , Wainwright, Mark, Zhou, Daniel J., Lattanzi, Simona, Navarro, Vincent, Hirsch, Lawrence J., Meletti, Stefano , Haider, Hiba A , Hanin, Aurélie , Giovannini, Giada , Orlandi, Niccolò , Urbano, Teresa , Malerba, Mara, Basha, Maysaa , Foreman, Brandon , Farias‐Moeller, Raquel , Gaspard, Nicolas , Gofton, Teneille , Gopaul, Margaret , Day, Gregory S. , Steriade, Claude , Struck, Aaron F. , Wainwright, Mark S. , Yoo, Ji Yeoun , Lattanzi, Simona , Navarro, Vincent , Hirsch, Lawrence J.

Mayo Clinic

JAMA Neurology | April 27, 2026 | Volume: 83 | Issue: 6 | Pages: 563

10.1001/jamaneurol.2026.0865 | PMID 42043830 Get It

Importance Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. Design, Setting, and Participants This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. Exposures Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). Main Outcomes and Measures Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. Results A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE—approximately 10-fold higher in CSF and 4-fold higher in serum—compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset ( P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). Conclusions and Relevance Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.
Monitored anaesthesia care without endotracheal intubation and general anaesthesia in pulsed field atrial fibrillation ablation
Wang, Weijia , Goel, Swecha, Estrada, Susan J, Hwang, Elliot , Obholz, Jacob, Dai, Qiying , Vidaillet, Humberto, Sharma, Param , Wang, Weijia , Kumar, Sanjay

Mayo Clinic

European Heart Journal Open | April 23, 2026 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/ehjopen/oeag070 | PMID 42125026 Get It

Abstract Aims Pulsed field ablation for atrial fibrillation offers shorter procedural times and improved safety compared with thermal ablation, but the optimal anaesthesia strategy remains uncertain. Most centres in the USA use general anaesthesia with endotracheal intubation, whereas monitored anaesthesia care without endotracheal intubation may be a safe and efficient alternative. Objectives To compare procedural efficiency and safety between monitored anaesthesia care and general anaesthesia for pulsed field ablation. Methods and results Consecutive adults who underwent pulsed field ablation for atrial fibrillation between 2024 and 2025 at Marshfield Clinic Health System were included. The anaesthesia approach was determined by operator preference. Procedural times, medication use, complications, and patient tolerance were recorded prospectively. Among 200 patients, 100 received monitored anaesthesia care without endotracheal intubation, and 100 received general anaesthesia. The mean age was 67 years, 42% were female, and the mean body mass index was 33 kilograms per square metre. Monitored anaesthesia care shortened case duration (77 vs. 95 min; P < 0.001) and laboratory time (118 vs. 153 min; P = 0.002) and required fewer adjunct medications (P < 0.001). Twenty-five procedures (25%) were challenging due to cough or motion but were all completed safely. Complications occurred in one monitored anaesthesia care case and six general anaesthesia cases (P = 0.054). Pulmonary vein isolation was achieved in all patients. Conclusion Monitored anaesthesia care without endotracheal intubation was safe, efficient, and resource-sparing compared with general anaesthesia for pulsed field atrial fibrillation ablation.
The Downstream Effects of Prehospital Opioid Dosing in Older Adults: A Retrospective Cohort Study
McGuire, Sarayna S. , Brown, Caitlin S. , Jeffery, Molly M. , Stanich, Jessica A. , Bower, Susan M. , Liedl, Chad P., Rentz, Lisa C, Bellolio, Fernanda , Jeffery, Molly Moore , Bellolio, M Fernanda , McGuire, Sarayna S , Palmer, Allyson K. , Mullan, Aidan F. , Bower, Susan M.

Mayo Clinic

Academic Emergency Medicine | April 23, 2026 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/acem.70294 | PMID 42023551 Get It

ABSTRACT Background Older adults experience age‐related physiological changes that alter the pharmacokinetics and pharmacodynamics of certain medications, which may necessitate reduced dosing. Our objective was to assess emergency department (ED) and hospital outcomes of older patients administered opioids by emergency medical services (EMS) clinicians. Methods Retrospective cohort study of adults ≥ 65 years who received an opioid between 2019 and 2024 within a health system‐affiliated EMS agency. We excluded patients with an advanced airway and those with no documented weight. Maximum single and cumulative weight‐based opioid dosages were classified as low, therapeutic, or high. Outcomes were measured in the ED/hospital and compared using Poisson regression with Huber/White standard errors, adjusted for age, sex, vitals, Glascow Coma Scale, emergency severity index, and chief concern. Results were reported as adjusted risk ratios (aRRs). Results A total of 6406 patients, including 747 (11.7%, 95% CI: 10.9–12.5) with a high opioid dose, 3663 (57.2%, 95% CI: 56.0–58.4) with a therapeutic dose, and 1996 (31.2%, 95% CI: 30.0–32.3) with a low dose, were included. Receipt of a high maximum single opioid dose versus a low/therapeutic dose (excluding patients receiving a concomitant sedative) was associated with increased risk of altered responsiveness (aRR = 1.28, 95% CI: 1.03–1.58) and delirium (aRR = 2.43, 95% CI: 1.08–5.45) in the ED/hospital setting. When 311 (4.9%) patients who received a concomitant sedative were included, patients who received a high opioid dose similarly had an increased risk of altered responsiveness (aRR = 1.28, 95% CI: 1.06–1.56) and delirium (RR = 2.65, 95% CI: 1.25–5.59), compared to a low/therapeutic dose. There was no difference in outcomes of hypoxia, death within 30 days, or ED length of stay between dose groups. Conclusion Prehospital administration of high opioid doses to older patients was associated with increased rates of altered responsiveness and delirium. These findings highlight how out‐of‐hospital care can impact a patient's ED and hospital course.
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention
Harrison, Theresa M., Harvey, Danielle J., Chadwick, Trevor, Chao, Yishu , Taggett, Jacinda , Maillard, Pauline, Lovato, Laura, Farias, Sarah, Papp, Kathryn V., Lockhart, Samuel N., Toga, Arthur W., Koeppe, Robert A., Jagust, William J., Whitmer, Rachel A., Snyder, Heather M. , Carrillo, Maria C., Baker, Laura D. , Espeland, Mark A., Vemuri, Prashanthi, DeCarli, Charles, Landau, Susan M., Harvey, Danielle , Carrillo, María C. , Harvey, Danielle J , Harrison, Theresa M. , Maillard, Pauline , Lovato, Laura, Farias, Sarah Tomaszewski , Papp, Kathryn V. , Lockhart, Samuel N. , Toga, Arthur W. , Koeppe, Robert A. , Jung, Youngkyoo , Jagust, William J. , Whitmer, Rachel A. , Espeland, Mark Andrew , Vemuri, Prashanthi , DeCarli, Charles , Landau, Susan

Mayo Clinic

JAMA Neurology | April 20, 2026 | Volume: 83 | Issue: 6 | Pages: 521

10.1001/jamaneurol.2026.0832 | PMID 42008251 Get It

Importance Brain imaging biomarkers may (1) identify underlying mechanisms of intervention effects and (2) define brain characteristics of those most likely to benefit cognitively from the intervention. Objective To test whether (1) a lifestyle intervention is related to brain changes, (2) brain changes are correlated with intervention-specific cognition changes, and (3) brain imaging biomarkers provide information about who is likely to benefit from a lifestyle intervention. Design, Setting, and Participants In this randomized clinical trial, the POINTER Imaging study was an ancillary study of the 2-year, single-blind multicenter US POINTER clinical trial in which neuroimaging data were collected on eligible enrolled participants. The study was conducted from May 2019 to March 2023 (final follow-up, May 14, 2025). Participants were enrolled into the POINTER Imaging study following a standard procedure at 5 clinical sites in the US. Participant eligibility criteria included an age of 60 to 79 years, sedentary lifestyle, and suboptimal diet, plus at least 2 additional risk criteria for cognitive decline and no contraindications for neuroimaging. Interventions Participants were randomly assigned to receive the structured or self-guided intervention. Both interventions emphasized increased physical and cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring, but they differed in intensity and accountability. Main Outcomes and Measures There were 4 primary imaging outcomes: global β-amyloid (Aβ) burden, tau burden in the entorhinal cortex (ERC), hippocampal (HC) volume, and white matter hyperintensity volume. The primary cognitive measure was a global cognitive composite. Results Among 1943 parent trial participants who were assessed for eligibility, 983 underwent at least 1 magnetic resonance imaging or positron emission tomography scanning session. The mean (SD) age was 68.4 (5.2) years; 605 participants (61.5%) were female and 378 male (38.5%). Five hundred sixteen participants received the structured intervention and 467 the self-guided intervention. There were no intervention group differences in longitudinal cognitive or imaging outcomes. Intervention group differences were not associated with or moderated by Aβ status or accumulation. There was a negative association between change in ERC tau and change in global cognition in the self-guided group that was attenuated in the structured group (difference in association: 0.289; 95% CI, 0.029 to 0.550; interaction P = .03). Lower baseline HC volume was associated with greater cognitive benefit for participants in the structured group vs the self-guided group (lower HC: 0.077 SD; 95% CI, 0.022 to 0.132; higher HC: 0.002 SD; 95% CI, −0.037 to 0.041; interaction P = .03). Conclusion and Relevance This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03688126
Abstract LB390: Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium
Zhang, Yifan , Cheng, Shuyan , Boddicker, Nicholas, Lebo, Matthew , Berry, Alexander S. , Hausler, Ryan , Desai, Heena, Rodriguez, Alex A , Hill, Andrew, Sheng, Xin, Gundell, Susan, Cicek, Mine S., Gignoux, Chris , Garraway, Isla P. , Pasaniuc, Bogdan, Oetjens, Matt, Kibel, Adam S., Kote-Jarai, Zsofia, Couch, Fergus J., Darst, Burcu F., Conti, David V., Haiman, Christopher A., Chen, F Z, Conti, David V. , Conti, David V , Boddicker, Nicholas , Haas, Roni , Dadaev, Tokhir , Desai, Heena , Madduri, Ravi , Sheng, Xin , Lilja, Hans , Melander, Olle , Paşaniuc, Bogdan , Boutros, Paul C. , Oetjens, Matthew T. , Kibel, Adam S. , Klein, Robert J. , Kote‐Jarai, Zsofia , Couch, Fergus J. , Maxwell, Kara N. , Darst, Burcu F. , Haiman, Christopher A.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB390-LB390

10.1158/1538-7445.am2026-lb390 Get It

Abstract Inherited susceptibility plays a critical role in prostate cancer (PCa) risk. Using large biobank and case-control datasets, we evaluated the contribution of both common variants and rare germline pathogenic variants (PVs) to overall PCa risk. The Prostate Cancer Exome Sequencing Consortium currently includes 427,388 male participants (51,452 PCa cases and 375,936 controls) with whole-exome sequencing data from ten biobanks and studies: UK Biobank (14,669 cases/195,600 controls), All of Us Research Program (7,577/75,226), African Ancestry Prostate Cancer Consortium (7,176/4,675), Mayo Clinic Biobank (6,031/15,084), Mass General Brigham Biobank (3,393/14,095), Geisinger’s MyCode Community Health Initiative (3,026/15,130), UCLA ATLAS Precision Medicine Biobank (2,850/16,904), Penn Medicine Biobank (2,598/16,255), Colorado Center for Personalized Medicine (2,269/13,399), and Malmo Diet and Cancer (1,863/9,568). Based on self-reported race/ethnicity and estimated genetic ancestry, the cases comprise approximately 79% European, 18% African, and 3% other ancestry populations. Single-variant association analyses tested all variants on chromosomes 1-22 and X with a minor allele count ≥ 5. In gene-based analyses, PVs were defined as rare variants (minor allele frequency [MAF] < 1% in controls) that had either a Variant Effect Predictor (VEP) impact score of “high” or a pathogenic or likely pathogenic ClinVar classification. Associations were estimated using Firth logistic regression, adjusting for age and the top ten genetic principal components. Results from individual studies were combined using fixed-effect meta-analysis. In single-variant association analyses, 496 variants reached genome-wide significance (p<5×10-8; MAF>0.02%). Among these, 458 (92%) variants mapped to previously known risk regions, including three rare PVs in HOXB13 (rs138213197), CHEK2 (rs555607708), and FAM111A (rs533676902). Characterization of the remaining 38 variants is ongoing. Gene-based analyses identified significant associations (p<2.4×10-6) for eight genes: HOXB13 (OR=3.7, 95% CI=3.3-4.2), BRCA2 (OR=2.0, 95% CI=1.7-2.3), CHEK2 (OR=1.6, 95% CI=1.5-1.8), ATM (OR=1.6, 95% CI=1.4-1.9), FAM111A (OR=1.4, 95% CI=1.3-1.5), BIK (OR=1.4, 95% CI=1.2-1.6), SAMHD1 (OR=2.1, 95% CI=1.6-2.7), and SMOC2 (OR=3.2, 95% CI=2.0-5.1). All genes except SMOC2 have been previously implicated in PCa susceptibility. Among cancer predisposition and DNA repair genes, nominal associations were also observed for XRCC2 (OR=1.6, 95% CIs=1.2-2.3) and BRCA1 (OR=1.2, 95% CI=1.0-1.4), whereas the association was not significant for PALB2 (OR=1.2, 95% CI=0.9-1.5). These findings reinforce the role of rare germline PVs, particularly in cancer predisposition and DNA repair genes, in PCa susceptibility. As additional studies are incorporated into the Consortium, we expect this work to provide a more comprehensive characterization of the genetic architecture of PCa. Citation Format: Yifan Zhang, Shuyan Cheng, Nicholas Boddicker, Matthew Lebo, Alexander S. Berry, Roni Haas, Ryan Hausler, Tokhir Dadaev, Heena Desai, Alex A. Rodriguez, Ravi K. Madduri, Andrew Hill, Xin Sheng, Susan M. Gundell, Mine Cicek, Penn Medicine Biobank, Olle Melander, Chris R. Gignoux, Isla P. Garraway, Bogdan Pasaniuc, Paul C. Boutros, Matt Oetjens, Adam S. Kibel, Robert J. Klein, Zsofia Kote-Jarai, Fergus J. Couch, Kara N. Maxwell, Burcu F. Darst, David V. Conti, Christopher A. Haiman, Fei Chen. Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB390.
Management of outpatient parenteral antibiotic therapy: a United States-based multi-center survey
Castellino, Laila M , Rivera, Christina G. , Beekmann, Susan E. , Mahoney, Monica V. , Keller, Sara C. , Mahoney, Monica V , Keller, Sara C , Rivera, Christina G , Beekmann, Susan E , Polgreen, Philip M.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | April 17, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2026.10347 | PMID 42038603 Get It

Abstract Objective: Outpatient parenteral antimicrobial therapy (OPAT) programs continue to evolve with increases in multidisciplinary teams, complex oral antibiotics, long-acting injectable antimicrobials, patients with substance use disorder (SUD) and telehealth. We sought to examine how OPAT programs are currently structured and identify barriers to safe care. Design: Cross-sectional survey. Participants: Physician, pharmacist, and advanced practice providers (APP) Emerging Infections Network (EIN) members. Methods: A survey was conducted between February and March 2025 to assess OPAT structure, expansion to complex outpatient antimicrobial therapy (COpAT), and barriers to safe OPAT care. Results: Of 1639 EIN members, 622 (38%) responded; 75% reported an active role in OPAT. Oversight of patients on COpAT was reported by 59%, and mandatory ID consultation for OPAT by 59%. Eighty-one percent reported >75% of OPAT patients were followed by ID. Most patients received OPAT at home (78%) followed by post-acute care facilities. Outpatient and inpatient ID physicians were responsible for laboratory test monitoring (75% and 30% respectively), while 37% reported a multidisciplinary OPAT team and 32% reported non-specialists. Respondents cited inadequate support in data analysis, administration, information technology and financial support for clinical staff. Common challenges were lack of leadership awareness (51%), difficulty managing patients with SUD (50%) and timely access to laboratory test results (48%). Conclusions: ID physicians were commonly involved in OPAT care, with many programs expanding to COpAT. Several barriers to the safe delivery of OPAT remain, including lack of institutional support, reimbursement and poor communication between stakeholders.
Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)
Kanoria, Shaveta , Miller, Melanie J., Aisen, Paul S., Beckett, Laurel A., Green, Robert C., Harvey, Danielle J., Jack, Clifford R., Jagust, William, Lee, Edward B., Nho, Kwangsik, Nosheny, Rachel, Okonkwo, Ozioma C., Perrin, Richard J., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Toga, Arthur W., Tosun, Duygu, Landau, Susan M., Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Harvey, Danielle , Weiner, Michael W , Harvey, Danielle J , Veitch, Dallas P. , Miller, Melanie J. , Aisen, Paul , Beckett, Laurel , Green, Robert C. , Jack, Clifford R. , Jagust, William J. , Lee, Edward B. , Nho, Kwangsik T. , Nosheny, Rachel, Perrin, Richard J. , Petersen, Ronald C. , Mindt, Mónica Rivera , Saykin, Andrew J. , Shaw, Leslie M. , Toga, Arthur W. , Landau, Susan , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | April 16, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71353 | PMID 41988903 Get It

Abstract Alzheimer's disease (AD) continues to pose a major public health challenge. Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has played a pivotal role in advancing the field by providing a comprehensive, open‐access, longitudinal dataset that integrates neuroimaging, biomarker, genetic, and clinical data related to AD. We used standard literature search methods to identify ∼1830 publications from 2023 to mid‐2025 that used ADNI data or samples. This review highlights key ADNI studies with direct clinical applications. We describe how these have impacted the development and validation of plasma biomarkers, improved clinical trials, assessed AD therapies, and developed methods for diagnosis and prediction using clinical, fluid, and imaging biomarkers. These contributions are underlain by an improved understanding of biological mechanisms of disease progression in AD and highlight ADNI's central role in advancing translational research and accelerating progress toward more effective, individualized care for patients with AD.
Distinct evolutionary patterns of endemic and emerging parvoviruses and the origin of a new pandemic virus
López-Astacio, Robert A. , Wasik, Brian R. , Lee, Hyunwook , Voorhees, Ian E. H. , Weichert, Wendy S. , Adu, Oluwafemi F. , Truyen, Uwe , Parrish, Colin R. , Truyen, Uwe , Parrish, Colin R , Goodman, Laura B. , Hafenstein, Susan

Mayo Clinic

Proceedings of the National Academy of Sciences | April 14, 2026 | Volume: 123 | Issue: 16 | Pages: No page available

10.1073/pnas.2515274123 | PMID 41980105 Get It

Emergence of epidemic viruses in new hosts threatens both human and other animal populations, and often involves virus evolution to overcome barriers that normally prevent efficient infection and spread in that host. After transfer the separated viruses will evolve in parallel as they spread within the original and new hosts. Here we examine the details of a virus involved in such a host-jumping event, where we define the natural evolution of feline panleukopenia virus (FPV) over 60 y, clarify the origins of the new pandemic canine parvovirus (CPV) that arose in the 1970s, and compare the separate evolution of those viruses over 47 y in cats or dogs. Several live-attenuated FPV vaccine viruses originated from early-1960s isolates or were a recombinant of an early virus, and many sequences in databases proved to be vaccine-derived. The sequences of wild viruses showed that FPV-like strains evolved at less than one-third the rate observed for CPV in dogs, and the higher rate of CPV evolution has been consistent since 1979, when a genetic variant became widespread. The common ancestor of the CPV lineage was related to FPVs from Europe and contained several unique host-adaptive capsid changes associated with canine transferrin receptor type-1 binding. Although the FPV vaccine strains are around 60 y old, little selection for antigenic variation was observed. The distinct evolutionary patterns of these closely related viruses circulating for decades in different hosts emphasize the complex evolution associated with viral epidemic emergence and spread in endemic and new hosts.